Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.
Posted inBusiness
Gates Foundation Pledges $120 Million to Help Get Covid Pills Quickly to Poor Countries
